Peptide questions · Eloralintide
How long does eloralintide take to work?
Reviewed Evidence: ModeratePublished by PepVault
Eloralintide’s onset is days–2 weeks, its peak effect comes at 48 weeks (phase 2 endpoint), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
The timeline’s basis: Phase 1 (Bhattachar 2026), phase 2 RCT (Billings 2025, Lancet; NCT06230523 posted results), Lilly releases Nov-6-2025, Sep-30-2026 and Nov-14-2026. Investigational.
Eloralintide week by week
The library places six of its research notes on eloralintide on the days they cover, from day 1 to day 336 and on: 4 on randomized trials and 2 on clinical data.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–28 (weeks 1–4) | Fullness first, gently | Randomized trial |
| Days 29–56 (weeks 5–8) | The step where nausea shows up | Randomized trial |
| Days 57–336 (weeks 9–48) | Holding at 6 mg | Randomized trial |
| Days 57–336 (weeks 9–48) | The top dose tested | Randomized trial |
| Days 85–336 (weeks 13–48) | Fewer cravings, quieter food noise | Clinical data |
| From day 337 on | A long-term medicine, not a course | Clinical data |

Model. Individual results vary.
The eloralintide timeline’s milestones
The library’s timeline for eloralintide marks 5 points from week 1 to week 48, backed by moderate evidence overall.
- Week 1: Commonly reported: feeling full sooner at meals, with nausea more likely on the higher doses
- Week 4: The phase 2 step-up arm moved from 3 mg to 6 mg after 4 weeks
- Week 8: The same arm moved to 9 mg from week 9
- Week 12: In phase 1, people on 12 mg had lost about 11% more than placebo by week 12
- Week 48: Phase 2 endpoint: about 9.5% (1 mg) to 20% (9 mg) average loss vs 0.4% on placebo
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why eloralintide takes that long
Eloralintide’s half-life is about 14 days (336 hours), so one dose is about 96.9% cleared after 70 days.
On its schedule (Weekly) the doses overlap, and the level of eloralintide keeps climbing for about 56–70 days before it levels off, so the first 56–70 days run below the level the later weeks hold.
The notes on eloralintide follow the trials’ dose steps, 3mg, 6mg and 9mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Eloralintide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, eloralintide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does eloralintide take to work?
Eloralintide’s onset is days–2 weeks, its peak effect comes at 48 weeks (phase 2 endpoint), and its typical duration is ongoing, by the library’s timeline (backed by moderate evidence).
When does eloralintide reach its peak effect?
By the library’s timeline, eloralintide’s peak effect comes at 48 weeks (phase 2 endpoint), backed by moderate evidence.
How long is eloralintide usually run?
The library’s timeline gives eloralintide’s typical duration as ongoing; its cycle note says: Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks.
What does the library say about the first days on eloralintide?
Its first note on eloralintide, for days 1–28 (weeks 1–4), is “Fullness first, gently”, resting on randomized trials.